Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Kristensen, Lasse Sommer ^a   Treppendahl, Marianne Bach ^a   Asmar, Fazila ^a   Girkov, Mia Seremet ^a   Nielsen, Helene Myrtue ^a,b   Kjeldsen, Tina Ellegaard ^b   Ralfkiaer, Elisabeth ^a   Hansen, Lise Lotte ^b   Grønbæk, Kirsten ^a  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DAPK1 PROTEIN, HUMAN; DEATH ASSOCIATED PROTEIN KINASE; DNA METHYLTRANSFERASE; DOXORUBICIN; MGMT PROTEIN, HUMAN; MONOCLONAL ANTIBODY; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PREDNISONE; R CHOP PROTOCOL; R-CHOP PROTOCOL; TUMOR SUPPRESSOR PROTEIN; VINCRISTINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER STAGING; CELL LINE; DNA METHYLATION; DNA SEQUENCE; FEMALE; GENETICS; GENOTYPE; HUMAN; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE; CYCLOPHOSPHAMIDE; DEATH-ASSOCIATED PROTEIN KINASES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOXORUBICIN; FEMALE; GENOTYPE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDNISONE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; VINCRISTINE; YOUNG ADULT;

EID: 84885169409     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02789     Document Type: Article

References (39)

1. Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343, 1350-4 (2000).
2. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003 (2005). (Pubitemid 40349502)
3. Esteller, M. et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94, 26-32 (2002).
4. Ohno, T. et al. Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma. Int J Hematol 83, 341-7 (2006). (Pubitemid 43807580)
5. Lee, G. W. et al. Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy? Leuk Lymphoma 50, 1992-8 (2009).
6. Pike, B. L. et al. DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia 22, 1035-43 (2008). (Pubitemid 351689886)
7. Hawkins, N. J. et al.MGMTmethylation is associated primarily with the germline C . T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol (2009).
8. Kristensen, L. S., Nielsen, H. M.,Hager, H. Hansen, L. L. Methylation ofMGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252MGMTpromoter SNP. Lung Cancer 71, 130-6 (2011).
9. Ogino, S. et al.MGMTgermline polymorphismis associated with somaticMGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 28, 1985-90 (2007). (Pubitemid 47514483)
10. Leng, S. et al. The A/G allele of rs16906252 predicts forMGMTmethylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas. Clin Cancer Res 17, 2014-23 (2011).
11. McDonald, K. L. et al. The T genotype of the MGMT C . T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. Eur J Cancer 49, 360-8 (2013).
12. Zochbauer-Muller, S. et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61, 249-55 (2001). (Pubitemid 32095725)
13. Mittag, F. et al. DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett 240, 69-75 (2006). (Pubitemid 44037174)
14. Amara, K. et al. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol 19, 1774-86 (2008).
15. Kristensen, L. S., Raynor, M. P., Candiloro, I. & Dobrovic, A. Methylation profiling of normal individuals reveals mosaic promoter methylation of cancerassociated genes. Oncotarget 3, 450-61 (2012).
16. Rand, K., Qu,W., Ho, T., Clark, S. J. Molloy, P. Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives. Methods 27, 114-20 (2002). (Pubitemid 34757121)
17. Shaw, R. J., Akufo-Tetteh, E. K., Risk, J.M., Field, J. K. & Liloglou, T.Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. Nucleic Acids Res 34, e78 (2006).
18. Mikeska, T. et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9, 368-81 (2007). (Pubitemid 47305073)
19. Candiloro, I. L. & Dobrovic, A. Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila Pa) 2, 862-7 (2009).
20. Herman, J.G., Graff, J. R.,Myohanen, S., Nelkin, B. D. Baylin, S. B. Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93, 9821-6 (1996). (Pubitemid 26296693)
21. Wong, H. L. et al. Rapid and quantitative method of allele-specific DNA methylation analysis. Biotechniques 41, 734-9 (2006).
22. Kristensen, L. S. & Hansen, L. L. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem 55, 1471-83 (2009).
23. Kristensen, L. S., Treppendahl, M. B. & Gronbaek, K. Analysis of epigenetic modifications of DNA in human cells. Curr Protoc Hum Genet 77, 20.2.1-20.2.22 (2013).
24. Xiong, Z. & Laird, P. W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25, 2532-4 (1997). (Pubitemid 27303718)
25. Guldberg, P., Worm, J. & Gronbaek, K. Profiling DNA methylation by melting analysis. Methods 27, 121-7 (2002). (Pubitemid 34757122)
26. Lade-Keller, J. et al. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneousmelanomas. JMol Diagn 15, 70-80 (2013).
27. Shoemaker, R., Deng, J., Wang, W. & Zhang, K. Allele-specific methylation is prevalent and is contributed by CpG-SNPs in the human genome. Genome Res 20, 883-9 (2010).
28. Kerkel, K. et al. Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet 40, 904-8 (2008).
29. Lee, S. M. et al. Prognostic significance of O6-methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B-cell lymphomas. APMIS 117, 87-94 (2009).
30. Hiraga, J. et al. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma. Int J Hematol 84, 248-55 (2006). (Pubitemid 44619247)
31. Amara, K. et al. Presence of simian virus 40 in diffuse large B-cell lymphomas in Tunisia correlates with germinal center B-cell immunophenotype, t(14;18) translocation, and P53 accumulation. Mod Pathol 21, 282-96 (2008). (Pubitemid 351304282)
32. Nakamichi, I. et al. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. Ann Hematol 86, 557-64 (2007). (Pubitemid 47018473)
33. Katzenellenbogen, R. A., Baylin, S. B. & Herman, J. G. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93, 4347-53 (1999). (Pubitemid 29279278)
34. Reddy, A. N. et al.Death-associated protein kinase promoter hypermethylation in normal human lymphocytes. Cancer Res 63, 7694-8 (2003). (Pubitemid 37466698)
35. Eads, C. A. et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28, E32 (2000).
36. Kristensen, L. S., Mikeska, T., Krypuy, M. & Dobrovic, A. Sensitive Melting Analysis after Real Time-Methylation Specific PCR (SMART-MSP): highthroughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res 36, e42 (2008).
37. Hansen, L. L., Andersen, J., Overgaard, J. Kruse, T. A. Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement. APMIS 106, 371-7 (1998). (Pubitemid 28157213)
38. Mikeska, T., Felsberg, J., Hewitt, C. A. & Dobrovic, A. Analysing DNA methylation using bisulphite pyrosequencing. Methods Mol Biol 791, 33-53 (2011).
39. Treppendahl, M. B. et al. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood 119, 206-16 (2012).